132 related articles for article (PubMed ID: 14710897)
1. Vaccine therapy for cutaneous T-cell lymphoma.
Seo N; Furukawa F; Tokura Y; Takigawa M
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1467-74. PubMed ID: 14710897
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.
Takigawa M; Tokura Y; Hashizume H; Yagi H; Seo N
Ann N Y Acad Sci; 2001 Sep; 941():139-46. PubMed ID: 11594567
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
4. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy.
Flacher V; Sparber F; Tripp CH; Romani N; Stoitzner P
Cancer Immunol Immunother; 2009 Jul; 58(7):1137-47. PubMed ID: 18677477
[TBL] [Abstract][Full Text] [Related]
5. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
6. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.
Berger CL; Longley J; Hanlon D; Girardi M; Edelson R
Ann N Y Acad Sci; 2001 Sep; 941():106-22. PubMed ID: 11594564
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.
Seo N; Tokura Y; Nishijima T; Hashizume H; Furukawa F; Takigawa M
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):371-6. PubMed ID: 10618425
[TBL] [Abstract][Full Text] [Related]
8. The current status and future direction of percutaneous peptide immunization against melanoma.
Seo N; Takigawa M
J Dermatol Sci; 2007 Nov; 48(2):77-85. PubMed ID: 17719748
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG; Karanikas V; Lurquin C; Colau D; Connerotte T; Hanagiri T; Van Pel A; Lucas S; Godelaine D; Lonchay C; Marchand M; Van Baren N; Boon T
Immunol Rev; 2002 Oct; 188():33-42. PubMed ID: 12445279
[TBL] [Abstract][Full Text] [Related]
10. Generation of dendritic cell-based vaccines for cancer therapy.
Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
[TBL] [Abstract][Full Text] [Related]
11. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
14. Current concepts of the immunobiology and immunotherapy of cutaneous T cell lymphoma: insights gained through cross-talk between the clinic and the bench.
Berger CL; Edelson RL
Leuk Lymphoma; 2003 Oct; 44(10):1697-703. PubMed ID: 14692521
[TBL] [Abstract][Full Text] [Related]
15. Vaccination therapy for cutaneous T-cell lymphoma.
Muche JM; Sterry W
Clin Exp Dermatol; 2002 Oct; 27(7):602-7. PubMed ID: 12464157
[TBL] [Abstract][Full Text] [Related]
16. Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization.
Fujiyama T; Oze I; Yagi H; Hashizume H; Matsuo K; Hino R; Kamo R; Imayama S; Hirakawa S; Ito T; Takigawa M; Tokura Y
J Dermatol Sci; 2014 Jul; 75(1):43-8. PubMed ID: 24802712
[TBL] [Abstract][Full Text] [Related]
17. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunotherapy by epicutaneous immunization requires langerhans cells.
Stoitzner P; Green LK; Jung JY; Price KM; Tripp CH; Malissen B; Kissenpfennig A; Hermans IF; Ronchese F
J Immunol; 2008 Feb; 180(3):1991-8. PubMed ID: 18209098
[TBL] [Abstract][Full Text] [Related]
20. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
